Secukinumab- Long term efficacy and safety in AS

Speciality: Rheumatology

Description:

A warm welcome to all the medical professionals in this interesting session on Secukinumab- Long term efficacy and safety in AS
Secukinumab is a monoclonal antibody that targets interleukin-17A (IL-17A) and has been approved for the treatment of ankylosing spondylitis (AS). Long-term studies have demonstrated its efficacy in reducing symptoms such as pain, stiffness, and inflammation in patients with AS. Clinical trials and real-world evidence have shown that patients receiving Secukinumab maintain significant improvements in disease activity and physical function over several years of treatment.
Regarding safety, long-term data indicates that Secukinumab has a favorable safety profile for AS patients. Common adverse effects include infections, such as upper respiratory tract infections, but these are generally manageable and do not outweigh the benefits of continued treatment. Serious adverse events are relatively rare, and the risk of malignancies, cardiovascular events, or other severe complications remains low with long-term use. The consistent efficacy and safety profile make Secukinumab a viable long-term treatment option for individuals with AS.
Therefore, get an overall knowledge of Secukinumab- Long term efficacy and safety in AS
 

See More Webinars @ Hidoc Webinars